Drug resistance in cancer: molecular evolution and compensatory proliferation

Ran Friedman

doi:10.18632/oncotarget.7459

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Drug resistance in cancer: molecular evolution and compensatory proliferation

Ran Friedman _

PDF | HTML | How to cite

Oncotarget. 2016; 7:11746-11755. https://doi.org/10.18632/oncotarget.7459

Metrics: PDF 2906 views | HTML 4413 views | ?

Abstract

Ran Friedman1

1 Department of Chemistry and Biomedical Sciences, Linnæus University, Kalmar, Sweden

Correspondence to:

Ran Friedman, email:

Keywords: nearly neutral theory; neoplasm; leukemia; bladder cancer; somatic mutations

Received: December 01, 2015 Accepted: February 08, 2016 Published: February 17, 2016

Abstract

Targeted therapies have revolutionized cancer treatment. Unfortunately, their success is limited due to the development of drug resistance within the tumor, which is an evolutionary process. Understanding how drug resistance evolves is a prerequisite to a better success of targeted therapies. Resistance is usually explained as a response to evolutionary pressure imposed by treatment. Thus, evolutionary understanding can and should be used in the design and treatment of cancer. In this article, drug-resistance to targeted therapies is reviewed from an evolutionary standpoint. The concept of apoptosis-induced compensatory proliferation (AICP) is developed. It is shown that AICP helps to explain some of the phenomena that are observed experimentally in cancers. Finally, potential drug targets are suggested in light of AICP.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7459

Publication Alerts

Post-Publication Promotion

Research Perspectives:

Drug resistance in cancer: molecular evolution and compensatory proliferation

Abstract